Slow Start to Q4 Healthcare Deals

October is typically a flighty month in the annual investing cycle. Spooky things can happen as the month winds down to Halloween. With the now-hot/now-not sentiments swirling around the equity markets, it was a relief not to witness a meltdown after all ended the month at or near new highs. The healthcare market wasn’t nearly […]

August Deal Flow Ebbs, as It Follows the Annual Cycle

Enough about slowdowns and recession. August is typically a roller-coaster month in the equity markets and August 2019 didn’t disappoint in that regard. The bond markets’ inverted yield curve persisted into September and that’s never a good sign. We’re moving on. Preliminary data show August’s deal volume wasn’t so bad, considering how most of 2019 […]

Summer Slowdown in Healthcare Deals Mixes with Global Uncertainty

After a slow first quarter, deal volume picked up again in the second. Pundits predicted a strong end to 2019, but the preliminary results from July’s deal making seem to indicate otherwise. With 126 transactions reported, July 2019’s deal volume sagged 17% compared with June’s and 18% against the same month in 2018. You may […]

Healthcare Dollar Volume Exploded in January

Dollar volume for healthcare deals announced in January was ridiculous, topping $90 billion. We don’t see figures like that in most quarters. The outsized total results from a single deal, of course. Bristol-Myers Squibb’s (NYSE: BMY) $74 billion acquisition of Celgene Corp. (NASDAQ: CELG) made up 81% of the month’s total. Suffice it to say […]